Showing 3971-3980 of 4164 results for "".
- Myopia Profile and Essilor Partner to Tackle Childhood Myopia Through Education and Awarenesshttps://modernod.com/news/myopia-profile-and-essilor-partner-to-tackle-childhood-myopia-through-education-and-awareness/2478446/Myopia educational company Myopia Profile and Essilor International announced their partnership to provide eye care practitioners with clinical knowledge, skills and practice in managing childhood myopia. The partnership will also see a boost to public awareness of the consequences of myopia, als
- New Orbis International Training Tool Prepares Ophthalmic Nurses for the Operating Roomhttps://modernod.com/news/new-orbis-international-training-tool-prepares-ophthalmic-nurses-for-the-operating-room/2478417/Orbis International announced the publication of the Orbis Ophthalmic Nursing Competency Assessment Rubric (ONCAR) for scrub nurses and technicians in Insight, the American Society of Ophthalmic Registered Nurses’ peer-reviewed clinical journal. The ONCAR is the first published tool
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Nicox Announces Plans for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-plans-for-ncx-4251-phase-2-trial-in-blepharitis/2478408/Nicox SA announced that the upcoming Mississippi phase 2 trial of its second clinical candidate, NCX 4251 0.1%, will be focused on acute exacerbations of blepharitis. If successful in meeting the primary endpoint for blepharitis previously agreed upon with the FDA, the trial could represent the f
- CooperVision Presents 6-Year Data from MiSight 1 Day Studyhttps://modernod.com/news/coopervision-presents-6-year-data-from-misight-1-day-study/2478397/CooperVision is reporting the latest findings from its landmark MiSight 1 day clinical study, providing new insights about myopia management and the efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children’s eyes originally fit with MiSigh
- Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practiceshttps://modernod.com/news/alcon-to-showcase-innovations-at-academy20-that-support-recovery-and-growth-for-eye-care-practices/2478379/Alcon will highlight leading innovations and clinical research at the 2020 American Academy of Optometry (#Academy20) meeting taking place virtually from October 7-22, 2020. The company’s virtual program will feature updates on its most important innovations, including Precision1 one-day contact
- New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluidhttps://modernod.com/news/new-phase-3-analysis-demonstrates-beovu-showed-improvement-in-bcva-in-wet-amd-patients-with-early-persistent-fluid/2478364/Novartis announced that results of two new post-hoc analyses of the phase 3 HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the Euretina 2020 virtual congress. The first analysis demonstrated fewer Beovu (brolucizumab) patients had early per
- Oculis Announces Presentation of Positive Results From Phase 2 Trial of OCS-01 in Patients With Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-presentation-of-positive-results-from-phase-2-trial-of-ocs-01-in-patients-with-diabetic-macular-edema-dme/2478362/Oculis announced that the positive results from the successful phase 2 (DX-211) clinical trial investigating OCS-01 for the treatment of diabetic macular edema (DME) were presented at Euretina 2020 Virtual during the Late Breaking & Reviews session on October 3. OCS-01 is a novel, high
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- Inovio’s COVID-19 Vaccine Candidate INO-4800 Hit by FDA Partial Holdhttps://modernod.com/news/inovios-covid-19-vaccine-candidate-ino-4800-hit-by-fda-partial-hold/2478341/Inovio Pharmaceuticals said that the FDA placed a partial clinical hold on a planned phase 2/3 study of its COVID-19 vaccine candidate INO-4800. According to Inovio, the FDA has “additional questions” about the planned trial, including the CELLECTRA 2000 delivery device to be